Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Antifection
    (2)
  • Apoptosis
    (2)
  • Autophagy
    (1)
  • Caspase
    (1)
  • FLT
    (1)
  • HIV Protease
    (1)
  • PI3K
    (1)
  • TAM Receptor
    (1)
  • Wnt/beta-catenin
    (1)
  • Others
    (17)
Filter
Search Result
Results for "

antileukemic activity

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    22
    TargetMol | Activity
  • Natural Products
    11
    TargetMol | inventory
Gilteritinib
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Microhelenin C
TN193263569-07-3
Microhelenin C has significant antileukemic activity.
  • $139
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Yadanzioside C
TN526595258-16-5
Yadanzioside C has antileukemic activity.
  • $670
Backorder
Size
QTY
Eucannabinolide
TN402738458-58-1
Eucannabinolide exhibits in vivo antileukemic activity.
  • $520
Backorder
Size
QTY
TargetMol | Inhibitor Sale
S-(N-PhenethylthiocarbaMoyl)-L-cysteine
T6055953330-02-2
S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys) is an anticarcinogenic agent that exhibits antileukemic activity by inhibiting DNA synthesis in HL60 cells [1] and acts as an inhibitor of P450 [2].
  • $2,140
6-8 weeks
Size
QTY
HDAC-IN-49
T73167
HDAC-IN-49 is a potent, non-selective inhibitor of HDAC (HDAC), demonstrating IC50 values of 13 nM for HDAC1, 14 nM for HDAC2, 21 nM for HDAC3, 1880 nM for HDAC4, and 10 nM for HDAC6. This compound exhibits significant antileukemic activity while maintaining low cytotoxicity towards healthy cells.
  • $1,520
6-8 weeks
Size
QTY
Yadanzioside G
TN232095258-17-6
Yadanzioside G has antileukemic activity.
  • $670
Backorder
Size
QTY
Moflomycin
T24492107430-03-5
Moflomycin is an anthracycline derivative. It exhibits a higher antileukemic activity compared to other anthracyclines.
  • $3,170
10-14 weeks
Size
QTY
(+)-Nortrachelogenin
TN467361521-74-2
(+)-Nortrachelogenin is a lignan isolated from Wikstroemia indica C.A. Meyer (Thymelaeaceae). (+)-Nortrachelogenin possesses antileukemic activity.
  • $130
In Stock
Size
QTY
Dehydrobruceantinol
TN379699132-99-7
Dehydrobruceantinol shows bitter taste and has antileukemic activity.
  • $820
Backorder
Size
QTY
Yadanzioside F
TN526695258-11-0
Yadanzioside F has antileukemic activity.
  • $670
Backorder
Size
QTY
PD 166326
T22132185039-91-2
PD166326, a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, demonstrates antileukemic activity with IC50 values of 6 nM for Src and 8 nM for Abl. [1] [2].
  • $1,140
6-8 weeks
Size
QTY
Yadanzioside A
TN231995258-15-4
Yadanzioside A has antileukemic activity.
  • $670
Backorder
Size
QTY
Hisphen
T255032764-56-9
Hisphen shows antileukemic activity.
  • $1,520
6-8 weeks
Size
QTY
Bruceantinoside A
TN354279439-85-3
Bruceantinoside A has antileukemic activity.
  • $740
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Botryodiplodin
T2517027098-03-9
Botryodiplodin, an antibiotic, has antileukemic activity from Botryodiplodia theobromae. It has the property of turning the skin of the individual in various shades of pink 2-3 hrs after application. It is a toxic metabolite of Penicillium carneo-lutescen
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
KPT-251
T242691388841-50-6
KPT-251 is a selective nuclear export inhibitor.
  • $148
In Stock
Size
QTY
(-)SHIN2
T73358
(+)SHIN2, an isomer of (-)SHIN2, is an inhibitor of serine hydroxymethyltransferase (SHMT) with antileukemic effects and shows synergistic activity with Methotrexate in in vivo xenotransplantation models [1].
  • $1,520
6-8 weeks
Size
QTY
Tagitinin F
TN509259979-57-6
Tagitinin F possesses antileukemic activity; it also shows in vitro leishmanicidal activities against Leishmania braziliensis promastigotes and amastigotes.
  • $550
Backorder
Size
QTY
Hepsulfam
T1547296892-57-8
Hepsulfam is an anticancer agent. It also displays excellent antileukemic activity (a median IC50: 0.91 μg mL in a panel of different tumors).
  • $140
5 days
Size
QTY
Triptonide
T5S105838647-11-9
1. Triptonide (PG 492) is effective in the treatment of autoimmune diseases and has potent antileukemic and antitumor activities. 2. Triptonide possesses anti-inflammatory activity, upregulate the expression of IL-37, and this expression was suppressed by ERK1/2 and p38 MAPK inhibitors.
  • $51
In Stock
Size
QTY
Caspase-3 activator 3
T82774
Caspase-3 activator 3 (compound 2h) effectively induces apoptosis in HL-60 and K562 cells by substantially activating caspase-3, demonstrating antileukemic activity with IC50 values of 42.89 μM and 33.61 μM, respectively [1].
  • Inquiry Price
Size
QTY